David Novack Sells 114,000 Shares of Dynavax Technologies (NASDAQ:DVAX) Stock

Dynavax Technologies Corporation (NASDAQ:DVAX) COO David Novack sold 114,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the sale, the chief operating officer directly owned 63,344 shares of the company’s stock, valued at $990,700.16. The trade was a 64.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $15.68 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. Dynavax Technologies Corporation has a 52-week low of $9.20 and a 52-week high of $15.73. The business’s 50 day simple moving average is $12.91 and its two-hundred day simple moving average is $11.26. The firm has a market cap of $1.84 billion, a P/E ratio of -42.38 and a beta of 0.89.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%.The company had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. As a group, research analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DVAX. William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $24.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. Hantz Financial Services Inc. increased its stake in Dynavax Technologies by 236.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 2,710 shares during the last quarter. LSV Asset Management purchased a new position in shares of Dynavax Technologies in the 3rd quarter worth approximately $89,000. Osaic Holdings Inc. grew its holdings in shares of Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,226 shares in the last quarter. Callan Family Office LLC bought a new position in shares of Dynavax Technologies in the second quarter valued at approximately $107,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Dynavax Technologies during the third quarter valued at approximately $109,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.